Sort   by:  
 Page size 
ProteomicsPatient anti-FVIII drug antibodies bind preferentially to a subset of FVIII covalent states
Haemophilia A is a chronic life-threatening condition caused by deficiency or dysfunction of plasma coagulation factor VIII (FVIII) and prophylaxis by regular infusion of FVIII protein is a common treatment. A major obstacle to FVIII replacement therapy is the generation of alloantibodies that dimin...
ORGANISM(S): Homo sapiens (Human) 
2025-08-04 | PXD060297 | Pride
Plasma Mass spec Fviii 
ProteomicsMHC class II presentation of FVIII-AnnexinA5 fusion proteins internalized by antigen presenting cells
The development of neutralizing antibodies (inhibitors) against coagulation factor VIII (FVIII) remains the most serious complication in the treatment of hemophilia A. While immune tolerance induction (ITI) is the standard strategy to eliminate these antibodies, it fails in approximately 30% of pati...
ORGANISM(S): Homo sapiens (Human) 
2025-10-20 | PXD068424 | Pride
Annexin a5 Phosphatidylserine Immune response Fviii Antigen presentation 
ProteomicsFVIII peptides presented on HLA-DP and identification of an A3 domain peptide binding with high affinity to the commonly expressed HLA-DP4
The development of neutralizing antibodies (inhibitors) against coagulation factor VIII (FVIII) poses a major challenge in hemophilia A (HA) treatment. The formation of FVIII inhibitors is a CD4+ T-cell-dependent mechanism which includes anti- gen presenting cells (APC), B- and T-helper lymphocytes....
ORGANISM(S): Homo sapiens (Human) 
2025-10-03 | PXD069096 | Pride
Hemophilia a Inhibitors Immunity Factor viii 
ProteomicsMechano‐covalent protection 1 of procoagulant factor VIII by von Willebrand factor
von Willebrand factor (VWF) is the protective carrier of procoagulant factor VIII (FVIII) in the shear forces of the circulation, prolonging its half‐life and delivering it to the developing thrombus. VWF∙FVIII complex formation is characterized by catch‐bond behavior in which force first decelerat...
ORGANISM(S): Homo sapiens (Human) 
2023-07-20 | PXD034866 | Pride
Cysteines Factor fviii Von willebrand factor Disulphide bonds 
ProteomicsExploring red blood cells as an antigen delivery system to modulate the immune response towards FVIII in hemophilia A
Background: The main complication in hemophilia A treatment is the development of inhibitory antibodies against factor (F)VIII. Immune tolerance induction, the gold standard for eradicating anti-FVIII antibodies, is efficient in only 60% to 80% of cases. This underscores the need for more efficient in...
ORGANISM(S): Homo sapiens (Human) 
2025-10-02 | PXD069058 | Pride
Hemophilia a Erythrocytes Inhibitors Immunity Factor viii 
TranscriptomicsRecombinant and plasma-derived Factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A
To investigate the gene expression in dendritic cells after treating hemiphilic mice with HBSS, plasma derived or recombinant factor VIII Gene expression in dendritic cells were measured 24 hours post treatment Hemophilic mice with treated with either (HBSS, rFVIII or pdFVIII) 24 hours post treatmen...
ORGANISM(S): Mus musculus 
2010-05-19 | E-GEOD-15809 | biostudies-arrayexpress
GenomicsGABARAPs proteins modulate FVIII secretion in molecule-specific manner via energy related pathways
GABARAPs proteins modulate FVIII secretion in molecule-specific manner via energy related pathways
PRJNA1120569 | ENA
TranscriptomicsGABARAPs proteins modulate FVIII secretion in molecule-specific manner via energy related pathways
Little is known about the biogenesis of Factor VIII (FVIII), its control of expression, intracellular trafficking, secretion, and associated cellular energy requirements. In this project, we employed a Y2H approach in to identify new interacting proteins that may play a role in the above mentioned p...
ORGANISM(S): Homo sapiens 
2026-06-30 | GSE269206 | GEO
UnknownA sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels.
Not available
S-EPMC1874571 | biostudies-literature
UnknownCovalent inactivation of factor VIII antibodies from hemophilia A patients by an electrophilic FVIII Analog.
Not available
S-EPMC2335366 | biostudies-literature
Sort   by:  
 Page size